ProBioGen, Nobelpharma Enter Mfg. Agreement for Vax Project

ProBioGen AG signed a service agreement for Nobelpharma’s vaccine project leveraging ProBioGen’s vaccine development platform consisting of its AGE1.CR.pIX suspension cell line and its high performance cell culture medium, for the propagation of Nobelpharma’s virus strain.

ProBioGen will apply state-of-the-art technologies to perform the upstream and downstream process development for Nobelpharma's highly relevant vaccine for large scale manufacturing.

The duck cell line AGE1.CR.pIX was designed to serve the industrial, GMP-compliant production of a wide variety of viruses in large bioreactors and is free of any adventitious agents. It has proven its great utility for viral vector production in various clinical trials.